CD163 and neoplasm: These results corroborate previous pilot in vivo experiments where mmHERA-CD40L reduced tumor volume of CT26 mice by 40% and an increase in F4/80 and CD8+ T cells together with a decrease in CD163 in the tumor was demonstrated (Supplemental Figure 6).